| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
|
|
05-10-2016, 04:25 PM
|
#1 | |||
|
||||
|
Member
|
http://www.msunites.com/genentech-to...us-april-20th/
http://www.nationalmssociety.org/Abo...erapy-Designat https://en.wikipedia.org/wiki/Ocrelizumab " Ocrelizumab is a slightly modified version of Biogen/Genentech's existing therapy Rituxan/Rituximab. As Rituxan was approaching FDA approval for treatment of multiple sclerosis, it was simultaneously approaching the end of its patent. To avoid the profit loss of a new treatment that could have been available sooner and eventually in a generic form, Rituxan trials were halted and Ocrelizumab trials quickly began. "
__________________
ditched the witch . |
|||
|
 Reply With Quote
|
| "Thanks for this!" says: | Kitty (05-10-2016) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Prana sounds Promising | Parkinson's Disease | |||
| Xcell Center update-sounds promising | Parkinson's Disease | |||
| Pain gene discovery - sounds promising | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
| new mouse model of PD-sounds promising | Parkinson's Disease | |||
| new med sounds promising.. | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Hybrid Mode
